期刊文献+

消囊方联合盐酸二甲双胍片治疗多囊卵巢综合征25例 被引量:3

下载PDF
导出
摘要 目的:观察消囊方联合盐酸二甲双胍片治疗多囊卵巢综合征的临床疗效。方法:将50例多囊卵巢综合征患者采用随机数字表法随机分为治疗组和对照组,对照组给予盐酸二甲双胍片治疗,治疗组在对照组用药基础上加服消囊方(茯苓、清半夏、苍术、制香附、陈皮、鸡血藤、枳壳、神曲、桃仁、丹参、夏枯草、生姜、甘草)。两组均以1个月为1个疗程,连用6个疗程。结果:两组治疗后胰岛素抵抗指数、高雄激素表现、身高、体质量、腰臀比指数、中医证候评分等指数方面明显优于对照组(P<0.05)。结论:消囊方联合盐酸二甲双胍片治疗多囊卵巢综合征可显著改善患者肥胖状况及高雄激素表现,有助提高患者妊娠率,值得临床推广。
出处 《中医研究》 2015年第6期15-17,共3页 Traditional Chinese Medicinal Research
基金 河南省中医药科学研究专项课题(2014ZY02101)
  • 相关文献

参考文献8

  • 1Wu XK, Pollanen P,Erkkola R. Selective ovarian resistance to insulin signaling in women with polycystic ovary syndrome[J]. Fertil Steril, 2003,80 ( 4 ) : 264 - 277.
  • 2Lopes-Virella MF,Klein RL,Virella G. Modification of lipo- proteins in diabetes[ J]. Diabetes Metab Rev, 1996,12( 1 ) : 69 - 90.
  • 3Ovalle F, Azzize R. Insulin resistance, polycystic ovary syn- drome, and type 2 diabetes mellitus [ J ]. Fertil Steril, 2002, 77(6) :1095.
  • 4李昕,林金芳.肥胖型多囊卵巢综合征患者临床及内分泌代谢特征的研究[J].中华医学杂志,2005,85(46):3266-3271. 被引量:139
  • 5Carm ina E,Ro sato F, J anniA,et al. Extensive clinical ex- perience: Relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperan- drogenism [ J ]. J Clin Endocrino 1M etab ,2006,91 (1) :226.
  • 6Azziz R, Woods KS, Reyna R, et al. The prevalence and fea- tures of the polycystic ovary syndrome in an unselected pop- ulation [ J ]. J Clin Endocrino IM etab, 2004, 89 (6) : 2745 - 2749.
  • 7戴春秀,王海波.多囊卵巢综合征的中医辨治思路[J].浙江中医药大学学报,2009,33(1):94-95. 被引量:10
  • 8梁静.孙维峰教授诊治多囊卵巢综合征的经验拾萃[J].中华中医药杂志,2008,23(10):900-901. 被引量:22

二级参考文献20

  • 1Pantanetti P, Garrapa GG, Mantero F, et al. Adipose tissue as an endocrine organ? A review of recent data related to cardiovascular complications of endocrine dysfunctions. Clin Exp Hypertens,2004,26:387-398.
  • 2Diamanti-Kandarakis E, BergieleA. The influence of obesity on hyperandrogenism and infertility in the female. Obesity Reviews ,2001, 2:231-238.
  • 3Ciampelli M , Leoni F , Lattanzi F , et al. A pilot study of the long 2 term effects of acipimox in polycystic ovarian syndrome. Hum Reprod, 2002 ,17:647-653.
  • 4Marsden PJ , Murdoch AP , Taylor R. Tissue insulin sensitivity and body weight in polycystic ovary syndrome. Clin Endocrinol , 2001 ,55:191-199.
  • 5Dunaif A. Insulin resistance and the polycystic ovary syndrome:mechanism and implications for pathogenesis. Endocr Rev, 1997,18 : 774 - 800.
  • 6Barzilai N, Wang J, Massilon D, et al. Leptin selesctively decreases visceral adiposity and enhances insulin action. J Clin Invest, 1997,100:3105-3110.
  • 7Farah L, Lazenby A J, Boots LR, et al. Prevalence of polycystic ovary syndrome in women seeking treatment from community electrologists(Alabama Professional Electrology Association Study Group ). J Reprod Med, 1999,44:870-974.
  • 8Diamanti-Kandarakis E, Kouli CR, Bergiele AT ,et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbost hormonal and metabolic profile. J Clin Endocrinol Metab, 1999, 84: 4006-4011.
  • 9Gambineril A, Pelusil C, Vicennatil V, et al. Obesity and the polycystic ovary syndrome. Int J Obesity, 2002,26:883-896.
  • 10Pasquali R, Casimirri F. The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women. Clin Endocrinol, 1993,39: 1-16.

共引文献165

同被引文献77

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部